Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Conditions
Interventions
CAB-AXL-ADC
PD-1 inhibitor
Locations
40
United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Tower Hematology Oncology Medical Group
Los Angeles, California, United States
Precision NextGen Oncology
Los Angeles, California, United States
UCSF Medical Center - Cancer Immunotherapy Clinic (CIC)
San Francisco, California, United States
Start Date
February 15, 2018
Primary Completion Date
January 8, 2025
Completion Date
January 8, 2025
Last Updated
September 23, 2025
NCT06422806
NCT04055220
NCT04332874
NCT05182164
NCT06277154
NCT05836571
Lead Sponsor
BioAtla, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions